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Chapter 1. 
 
Preface 
 
Atopic dermatitis is the most common skin disease, affecting a large number of 
children, adults, and their families (Table 1-1) (1). Worldwide prevalence of atopic 
dermatitis ranges from 0.2 to 25%, and the prevalence in developing countries has 
markedly increased in recent decades. In developed countries with the highest 
prevalence, the disease has reached a steady level (2, 3). The natural course of atopic 
dermatitis varies. In one type, initial onset is in infancy (early onset) then subsides 
before age 2; another type starts in infancy then gradually subsides; a type that once 
cured, recurs after puberty; and a type with initial onset at age 5 or over (4). When 
initial onset is in infancy, it is frequently accompanied by food allergies. In some 
patients, it is known to occur with bronchial asthma, allergic rhinitis and conjunctivitis 
(5). 
Atopic dermatitis is defined as a disease characterized primarily by pruritic 
eczema that repeats a pattern of remission and exacerbation, and most frequently occurs 
in patients with atopic diathesis. Atopic dermatitis is diagnosed when the following 
three symptoms are clinically presented, regardless of the severity of symptoms: 
pruritus, a characteristic rash and distribution, and a chronic or relapsing course (6, 7, 
8). The pathogenesis of atopic dermatitis is attributed to complex interactions between 
the environment and host susceptibility genes, which alter skin barrier function and the 
immune system (9). Most patients with atopic dermatitis can control their skin disease 
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with topical therapy and skin care (Figure 1-1). However, eczematous skin lesions in 
some patients do not respond to treatment with moisturizers, topical corticosteroids or 
topical calcineurin inhibitors, while some patients experience immediate flare-ups after 
tapering topical anti-inflammatory therapy (1, 10). Furthermore, sleep loss due to 
itching are significant, and affect not only patient’s quality of life (QOL) but also QOL 
of the patient’s caregiver such as parent (11). There is an unmet need for new medical 
treatment options for these patients and their caregivers. 
Atopic dermatitis is a subtype of eczema/dermatitis, and infiltration of 
inflammatory cells including lymphocytes, eosinophils, and mast cells are present in 
eczema lesions (12, 13). Leukocytes from patients with atopic dermatitis display 
reduction of cyclic adenosine monophosphate (cAMP) responses, which is an 
intracellular signal molecule associated with various cellular responses (14). 
Intracellular cAMP levels are controlled by adenylate cyclase and phosphodiesterase 
(PDE) (Figure 1-2). PDE include a number of different isozymes (Table 1-2), and PDE 
type 4 (PDE4), the one most involved in this type of inflammatory reaction, plays an 
important role in activation of inflammatory monocytes and T cells (15, 16). PDE4 
activity is elevated in the leukocytes of patients with atopic dermatitis, and leading to 
leukocyte hyperactivity and inflammation (17–19). 
Although inhibition of PDE4 activity in inflammatory cells is a new target of 
atopic dermatitis and several PDE4 inhibitors have been developed, their use has thus 
far been compromised by the occurrence of mechanism-associated adverse reactions, 
including nausea, vomiting, headache, and weight loss, which often limit the maximum 
tolerated dose (20, 21). Therefore, to minimize systemic exposure, a topically active 
PDE4 inhibitor with low transdermal bioavailability could be clinically useful. 
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E6005 (molecular weight: 472.49) is developed as a novel PDE4 inhibitor for 
the topical treatment of atopic dermatitis (Figure 1-3). E6005 shows potent and selective 
inhibition of PDE4, and suppresses cytokine production by lymphocytes and monocytes 
(22). In hapten-elicited mice models, the topical application of E6005 produces 
anti-inflammatory effects, with reduced expression of cytokines and adhesion molecules. 
In addition, topical E6005 ameliorates the appearance of atopic dermatitis-like skin 
lesions in hapten- and mite-elicited models (22, 23). The use of 14C-labeled E6005 
shows rapid clearance from the blood and low distribution to the brain, contributing to 
the low emetic potential (22). 
Additionally, depolarization of dorsal root ganglion neurons by capsaicin (a 
transient receptor potential vanilloid 1 activator) is attenuated by E6005 as well as by 
forskolin (a cAMP elevator). E6005 elevated intracellular levels of cAMP in dorsal root 
ganglion cells (24). Alternatively, in NC/Nga mice with chronic dermatitis, topical 
E6005 inhibits spontaneous hind-paw scratching, an itch-associated response and 
spontaneous activity of the cutaneous nerve. The cutaneous concentration of cAMP is 
significantly decreased in mice with chronic dermatitis, and this decrease is reversed by 
topical E6005 application (25). Topical E6005 inhibits scratching and cutaneous nerve 
firing induced by SLIGRL-NH2 (a proteinase-activated receptor 2 agonist peptide). 
PDE4 subtypes are mainly expressed in keratinocytes and mast cells in the skin (26). 
These results suggest that E6005 may be a promising novel therapeutic agent 
with antipruritic activity for the treatment of atopic dermatitis. Therefore, in chapter 2, I 
plan to conduct a randomized, investigator-blind, vehicle-controlled, multiple ascending 
dose study to evaluate the safety and pharmacokinetics of E6005 ointment in healthy 
volunteers (27). I show that E6005 ointment (0.01–0.2%) does not induce skin irritation, 
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light urticaria, or phototoxicity, and that E6005 application for 5 days is well tolerated. 
No clinical concerns are found in terms of adverse events, clinical laboratory tests, vital 
signs, electrocardiograms, and ophthalmology. Plasma concentrations of E6005 and 
M11 (Figure 1-3), a hydrolyzed metabolite, are below the limit of quantification at all 
the sampling points. This result suggests that topical application of E6005 ointment 
results in very low systemic exposure to E6005 in healthy volunteers. 
In chapter 3, I plan to conduct a randomized, investigator-blinded, 
vehicle-controlled, multiple ascending dose study to evaluate the safety, tolerability and 
pharmacokinetics of E6005 ointment in patients with atopic dermatitis, and to assess the 
efficacy of E6005 (27, 28). I show that E6005 ointment (0.01–0.2%) application for 10 
days is safe and well tolerated. Although E6005 is not detected in the plasma of any 
patients, the metabolite M11 is detected in the plasma of three. This result suggests 
absorption of E6005 is restricted by the stratum corneum, absorbed E6005 is rapidly 
metabolized to M11, and it is eliminated from the systemic circulation in humans. 
Patients receiving the 0.1% or 0.2% E6005 treatment have significantly greater 
improvement in most efficacy parameters than patients receiving the vehicle treatment. 
These results suggest that E6005 ointment can provide a new treatment option for atopic 
dermatitis that avoids safety concerns associated with PDE4 inhibitors, while 
maintaining similar effectiveness. 
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Table 1-1 Population (000s) & Prevalence (%) 
DATAMONITOR. Stakeholder Opinion: Atopic Dermatitis (Reference Code: DMHC2279). 2007. 
 
Age Japan US UK France Germany Spain Italy Total 
Infant 
(0-4) 
1,180 
(20.3%) 
4,455 
(21.5%) 
713 
(21.5%) 
797 
(21.5%) 
734 
(21.5%) 
493 
(21.5%) 
569 
(21.5%) 
8,941 
Child 
(5-14) 
2,160 
(18.0%) 
7,123 
(17.2%) 
1,047 
(14.6%) 
687 
(9.4%) 
539 
(6.8%) 
186 
(4.6%) 
310 
(5.7%) 
12,052 
 
Adult 
(≥15) 
3,646 
(3.3%) 
7,960 
(3.3%) 
1,634 
(3.3%) 
1,647 
(3.3%) 
2,351 
(3.3%) 
1,229 
(3.3%) 
1,652 
(3.3%) 
20,119 
Total 6,986 19,538 3,394 3,131 3,624 1,908 2,531 41,112 
(5.6%) 
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Table 1-2 PDE family 
Family Gene Sub- strate 
Tissue/ 
Cellular Function Inhibitor 
(All)     
Theophylline is an unspecific 
PDE inhibitor, a currently 
approved treatment for asthma or 
other lung diseases (eg, 
emphysema, bronchitis). 
 
Common side effects: headache, 
nausea, diarrhea, trouble sleeping  
PDE1 
PDE1A 
PDE1B 
PDE1C 
cAMP 
cGMP 
Brain 
Smooth muscle 
Heart 
etc 
Calcium/calmodulin-regulated PDE 
PDE1A probably serves to regulate 
vascular smooth muscle contraction and 
may play a role in sperm function 
PDE1B is involved in dopaminergic 
signaling as well as immune cell 
activation and survival 
PDE1C is required for vascular smooth 
muscle cell proliferation and may also 
regulate sperm function and neuronal 
signaling 
Vinpocetine is a Dietary 
supplement of memory 
enhancement and cognitive 
improvement 
PDE2 PDE2A  
Adrenal medulla, 
Brain 
Heart 
etc 
cGMP-stimulated PDE 
PDE2 frequently mediates cross-talk 
between cGMP and cAMP pathways; it 
regulates aldosterone secretion from the 
adrenal gland, cAMP and PKA 
phosphorylation of Ca2 channels in the 
heart, cGMP in neurons, long-term 
memory, and barrier function of 
endothelial cells under inflammatory 
conditions 
EHNA (erythro-9-(2-hydroxy- 
3-nonyl)adenine) is investigated 
for improving memory in animal 
models. 
PDE3 PDE3A PDE3B cAMP 
Heart 
Smooth muscle 
Platelets 
Adipocyte 
etc 
cGMP-inhibited PDE 
PDE3A regulates cardiac contractility, 
platelet aggregation, vascular smooth 
muscle contraction, oocyte maturation, 
and regulation of renin release 
PDE3B mediates insulin signaling, 
especially its antilipolytic effects; 
PDE3B also regulates cell 
cycle/proliferation and mediates the 
inhibitory effects of leptin and other 
signals on insulin secretion and renin 
release 
Milrinone is a currently 
approved treatment for short term 
congestive heart failure 
Cilastazol is a treatment for 
intermittent claudication 
 
Common side effects: diarrhea, 
headache, and nausea 
PDE4 
PDE4A 
PDE4B 
PDE4C 
PDE4D 
cAMP a variety of tissues 
cAMP-specific PDE 
At least one form is expressed in most 
cells, and PDE4s play roles in a wide 
array of processes, including brain 
function, monocyte and macrophage 
activation, neutrophil infiltration, 
vascular smooth muscle proliferation, 
fertility, vasodilation, and cardiac 
contractility 
Roflumilast is a currently 
approved treatment for chronic 
obstructive pulmonary disease 
Apremilast is a currently 
approved treatment for psoriasis 
and psoriatic arthritis 
 
Common side effects: diarrhea, 
headache, and nausea 
PDE5 PDE5A cGMP 
Platelets 
Smooth muscle 
Brain 
etc 
cGMP-binding, cGMP-specific PDE 
PDE5 is a well-documented regulator of 
vascular smooth muscle contraction, 
especially in penis and lung; it is 
involved in NO-cGMP signaling in 
platelets to control aggregation and may 
also play a role in regulation of cGMP 
signaling in the brain 
Sildenafil, vardenafil, and 
tadalafil are a currently approved 
treatment for erectile dysfunction 
drugs and pulmonary 
hypertension. 
 
Common side effects: headache, 
flushing, dyspepsia, abnormal 
vision, nasal congestion, back 
pain, myalgia, nausea, dizziness, 
and rash 
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Family Gene Sub- strate 
Tissue/ 
Cellular Function Inhibitor 
PDE6 
PDE6A 
PDE6B 
PDE6C 
cGMP Retina 
Photoreceptor 
PDE6 is involved in signal transduction 
of the photoresponse in the eye; it may 
also regulate melatonin release from the 
pineal gland 
 
PDE7 PDE7A PDE7B cAMP 
Immune cell 
Skeletal muscle 
Brain 
etc 
Rolipram-insensitive PDE 
PDE7 is implicated to play a role in 
T-cell activation and activation of other 
inflammatory cells 
 
PDE8 PDE8A PDE8B cAMP 
Immune cell 
Liver, 
Kidney 
Testis, 
Thyroid 
etc 
cAMP-specific PDE 
PDE8 may play a role in T cell 
activation, sperm, or leydig cell function 
 
PDE9 PDE9A cGMP 
Brain 
Kidney 
etc 
cGMP-specific PDE 
The function of PDE9 is currently 
unknown, but it has been postulated to 
regulate NO-cGMP signaling in the 
brain 
 
PDE10 PDE10A cAMP cGMP 
Brain 
Testis 
etc 
cAMP-inhibited，dual-substrate PDE 
PDE10A is thought to be a regulator of 
cGMP in the brain and may play a role 
in learning and memory 
 
PDE11 PDE11A cAMP cGMP 
Skeletal muscle 
Testis 
Prostate 
etc 
Dual-substrate PDE 
PDE11 possibly has a role in sperm 
development and function 
 
Bender AT, Beavo JA. (2006) Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use. Pharmacol Rev. 58, 
488 – 520. 
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Recalcitrant, severe AD Step 4 
 
 Systemic Therapy (e.g. CyA) or UV therapy 
 Mid-high potency TCS and/or TCI 
 Basic treatment 
  
Moderate to severe AD Step 3 
 Mid-high potency TCS and/or TCI 
 Basic treatment 
  
Mild to moderate AD Step 2 
 Low-Mid potency TCS and/or TCI 
 Basic treatment 
  
Dry skin only Step 1 
 Basic treatment 
Skin hydration, emollients, avoidance of irritants, 
Identification and addressing of specific trigger factor 
  
 
Figure 1-1 Stepwise management of patients with atopic dermatitis 
AD: atopicdermatitis, CyA: cyclosporin A, TCI: topical calcineurin inhibitor, TCS: topical corticosteroid, UV: ultraviolet 
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A Basal PDE activity: resting state 
 
 
B Increased cAMP: PKA activation 
 
 
C PDE phosphorylation and activation: reduction in cAMP level 
 
 
Figure 1-2 Regulation of cAMP level 
AC: adenylyl cyclase, AMP: adenosine monophosphate, ATP: adenosine triphosphate, cAMP: 3’,5’-cyclic AMP, CREB: cAMP 
response element binding protein, CSK: C-terminal Src kinase, Gβγ: G protein βγ subunit, Gsα: stimulatory G protein α subunit, 
GPCR: G protein coupled receptor, mAKAP: membrane A-kinase anchor protein, PDE: phosphodiesterase, TCR: T-cell receptor 
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A E6005 B M11 (a hydrolyzed metabolite) 
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Figure 1-3 E6005 and M11 
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Chapter 2. 
 
A Phase I, Multiple-dose Study of E6005 Applied Topically to 
the Skin of Healthy Japanese Adult Subjects 
 
Summary 
 
Objectives: The purpose of the present study was to assess the safety, tolerability and 
pharmacokinetics of topical application of a novel phosphodiesterase inhibitor, E6005, 
in healthy volunteers. 
Methods: A randomized, investigator-blind, vehicle-controlled study was conducted to 
evaluate the topical application of E6005 ointment at concentrations ranging from 
0.01% to 0.2% in healthy volunteers (Study 001). 
Results: Thirty-six subjects were enrolled in Study 001. Neither skin irritation nor 
photosensitization was observed with application of E6005 in Study 001. Four subjects 
receiving E6005 in Study 001 experienced a treatment-emergent adverse event 
(application site edema, increased alanine aminotransferase or erythema); three of these 
subjects discontinued the study. Plasma concentrations of E6005 were below the limit 
of quantification (1 ng/ml). 
Conclusion: E6005 ointment exhibited acceptable safety and tolerability. Topical 
application of E6005 ointment resulted in very low systemic exposure to E6005 in 
healthy volunteers. 
12 
 
Introduction 
 
Atopic dermatitis is a chronic, inflammatory, pruritic skin disease that affects 
large numbers of children, adults and their families in industrialized countries (7). The 
pathogenesis of atopic dermatitis is attributed to complex interactions between the 
environment and host susceptibility genes, which alter skin barrier function and the 
immune system (29). It has been known since the 1980s that leukocytes from patients 
with atopic dermatitis display reduced cyclic adenosine monophosphate (cAMP) 
responses to stimulation (14) and elevated phosphodiesterase (PDE) activity, leading to 
leukocyte hyperactivity and inflammation (17–19). 
Several PDE type 4 (PDE4) inhibitors have been developed to treat chronic 
inflammatory disorders. For example, roflumilast is approved as an oral add-on therapy 
for chronic obstructive pulmonary disease (30), and apremilast has been developed to 
treat psoriasis (31). However, the clinical utility of PDE4 inhibitors has so far been 
compromised by the occurrence of mechanism associated adverse reactions, including 
nausea, vomiting, headache and weight loss, which often limit the maximum tolerated 
dose (20, 21). However, a topically active PDE4 inhibitor with low transdermal 
bioavailability could be clinically useful. 
To minimize systemic exposure, E6005 (molecular weight: 472.49) was 
developed as a novel PDE4 inhibitor for topical use (22). E6005 has shown potent and 
selective inhibition of PDE4, and suppresses the production of proinflammatory 
cytokines by human lymphocytes and monocytes (22). In mouse models, E6005 
ointment application has shown an immediate antipruritic effect, as well as an 
anti-inflammatory effect, with reduced expression of cytokines and adhesion molecules 
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(22). A randomized, investigator-blind, vehicle-controlled, multiple ascending dose 
study was conducted to evaluate the safety and pharmacokinetics of E6005 ointment in 
healthy volunteers. 
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Materials and Methods 
 
E6005 ointment in a base of white petrolatum (Eisai Co., Ltd., Tokyo, Japan) 
was evaluated. The primary objective of E6005-J081-001 (Study 001) was to assess the 
safety and pharmacokinetics of E6005 applied repeatedly to the skin of healthy Japanese 
men at concentrations of 0.01%, 0.03%, 0.1% or 0.2%, compared with vehicle. This 
study was conducted at the Sekino Clinical Pharmacology Clinic, Tokyo, Japan, in 2009. 
Study 001 was performed in full compliance with the International Conference on 
Harmonisation, all applicable Good Clinical Practice guidelines and local regulations in 
Japan, and was approved by the institutional investigational review boards. All the 
patients provided written informed consent. 
 
Study subjects 
Eligible participants met all of the inclusion criteria but none of the exclusion 
criteria were enrolled in the study. 
Inclusion Criteria: 
 Healthy Japanese adult males 
 Subjects who were given a full explanation about the objective and details of this 
study before starting screening and who gave written consent based on their free 
will 
 Subjects who were ≥20 years old and <45 years old at the time of obtaining written 
consent 
 Body Mass Index (BMI [kg/m2] = weight [kg] / height [m] × height [m]) was 
≥18.5 kg/m2 and <25.0 kg/m2 at the time of screening 
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 Subjects who were considered to be eligible for study entry by the investigator or 
subinvestigator based on the screening assessment performed within 4 weeks prior 
to the first drug application 
Exclusion Criteria: 
 Subjects with a present illness or a history of allergy to drugs or foods, or clinically 
significant allergy (e.g., metal allergy, chronic asthma) 
 Subjects with cutaneous hypersensitivity or photosensitivity to any dermatologic 
agents (e.g., plaster, transdermal drugs) 
 Subjects with dermatitis or eczema, or those diagnosed by the investigator or 
subinvestigator as having other abnormal dermal conditions 
 Subjects with gastrointestinal, hepatic, renal, respiratory, endocrine, hematological, 
neurological, psychiatric, or cardiovascular disorders and/or inborn error of 
metabolism that may influence the evaluation of the investigational drug at the time 
of screening or within 4 weeks prior to the first drug application 
 Subjects with a known history of any surgical treatment (e.g., hepatectomy, 
nephrotomy, gastrointestinal resection) that may affect the pharmacokinetics of the 
investigational drug 
 Subjects who experienced a 10% or more weight gain or loss between the time of 
screening and the day before the first drug application 
 Subjects who consumed caffeine-containing beverage or food (coffee, tea, 
chocolate, coke, etc.) within 72 hours prior to the first drug application 
 Subjects who consumed alcohol within 72 hours prior to the first drug application 
 Subjects who smoked or consumed nicotine-containing material within 4 weeks 
prior to the first drug application 
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 Subjects who engaged in heavy exercise or labor within 2 weeks prior to the first 
drug application 
 Subjects who were found to have clinically abnormal findings requiring medical 
treatment(s) in the medical history, signs and symptoms, vital signs, ECG or 
laboratory tests, or those with impaired organ functions 
 Subjects with QTc >450 msec in the screening 12-lead ECG 
 Subjects whose systolic blood pressure was ≥130 mmHg and/or diastolic blood 
pressure was ≥85 mmHg at the time of screening 
 Subjects whose pulse rate was <50 bpm and/or ≥100 bpm at the time of screening 
 Subjects with a known or suspected history of alcohol or drug abuse, or those who 
were positive for urine drug screening 
 Subjects who received prescription drugs within 4 weeks prior to the first drug 
application 
 Subjects who received OTC medications, nutritional supplements, vitamins, and/or 
herbal preparations (including oriental medicines) within 1 week prior to the first 
drug application. Subjects who received herb preparations that are known to be 
cytochrome P450 enzyme inducer (e.g., St. John’s Wort preparations) within 
4 weeks prior to the first drug application 
 Subjects who received another investigational drug or used another investigational 
medical device within 16 weeks prior to the first drug application 
 Subjects who received blood transfusion within 12 weeks prior to, those who 
donated 400 mL or more whole blood within 12 weeks prior to, those who donated 
200 mL or more whole blood within 4 week prior to, or those who donated 
component blood within 2 weeks prior to the first drug application 
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 Subjects with a history of infection requiring medical treatment within 4 weeks 
prior to the first drug application 
 Subjects who were positive for hepatitis B surface antigen (HBs antigen), 
hepatitis C virus (HCV) antibody, or a serologic test for syphilis 
 Subjects who were diagnosed with acquired immunodeficiency syndrome (AIDS), 
or those who were positive for the human immunodeficiency virus (HIV) antibody 
 Subjects who were unwilling to or unable to abide by the requirements of this study  
 Subjects whom the investigator or subinvestigator considered ineligible for study 
entry 
 
Investigational drugs 
In present study, white petrolatum, E6005 (Methyl 4-[({3-[6,7-dimethoxy-2- 
(methyl amino)quinazolin-4-yl]phenyl}amino)carbonyl]benzoate, molecular 
weight: 472.49) ointment and vehicle (ointment base that did not include E6005) were 
used. E6005 ointment and vehicle were manufactured by Eisai Co, Ltd. 
 
Study design 
In Study 001, participants were divided into four cohorts of nine subjects each, 
according to the concentration of E6005 ointment applied (0.01%, 0.03%, 0.1% or 
0.2%). Seven subjects in each cohort were randomly selected to receive E6005 ointment 
application, while two received vehicle application. Each cohort participated in two 
testing periods (Figure 2-1, Table 2-1). In Period I, approximately 30 mg of the 
investigational drugs (no treatment; white petrolatum; vehicle; 0.01%, 0.03%, 0.1% and 
0.2% E6005) were individually placed in two sets of Finn Chambers® (Epitest Ltd Oy, 
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Tuusula, Finland) for patch and photopatch testing. The Finn Chambers® were applied 
to the outer surface of the upper arms on day 1. In the first half of Period II, a simple 
application of the investigational drug was applied to the posterior trunk at dosages of 
1 g in the morning on day 9, 2 g in the morning on day 11 and 5 g in the morning on 
day 13. In the second half of Period II, on days 15–19, repeated 5 g doses were applied 
in the morning and at night. The type of ointment applied (E6005 or vehicle) was 
masked to assessment investigators and to subjects. When no safety concerns arose 
within a cohort, the next cohort was started with a higher E6005 concentration. 
 
Assessments 
In the patch test (skin irritation test), the investigational drugs were applied to 
the skin for 48 h. Skin reactions were assessed 30 min and 24, 72 and 120 h after 
removing the Finn Chamber®, according to the criteria of the International Contact 
Dermatitis Research Group (32) and Japanese criteria (33). 
In the photopatch test (photosensitivity test), the investigational drugs were 
applied for 24 h. The skin was then exposed to long-wavelength irradiation (UVA, 
6 J/cm2). The presence or absence of light urticaria was assessed 30 min after optical 
irradiation, and the site was then covered with a new empty Finn Chamber® for 1 day. 
Skin reactions were assessed 24, 48, 96 and 144 h after optical irradiation, according to 
the criteria of the International Contact Dermatitis Research Group (34) and Japanese 
criteria (33). 
All the skin reactions were assessed by a physician who was kept blind to the 
preparation sequence. The assessor did not apply or remove the preparations during the 
study and was never told the preparation sequence. A photograph of the application site 
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was taken before application and at the time of assessment. 
The safety profile was assessed with treatment-emergent adverse event 
reporting, based on the Common Terminology Criteria for Adverse Events (National 
Cancer Institute, Bethesda, MD, version 4.02), clinical laboratory testing, 
electrocardiogram recording, vital signs and ophthalmological findings. 
 
Measurement of plasma concentrations of E6005 and its metabolite 
In Study 001, blood samples were collected for assessment of 
pharmacokinetics before initial treatment, before dosing on days 8, 9, 11, 13, 15 and 19, 
and at 1-, 2-, 4- and 8-h post-dose on days 15 and 19. Plasma concentrations of E6005 
and its major metabolite (the methyl ester hydrolysis product) were quantified with a 
validated liquid chromatography-tandem mass spectrometry method with a lower limit 
of quantification of <1 ng/ml (35). 
 
Statistical analysis 
Randomization schedules were generated by the SAS RANUNI procedure. All 
the analyses were performed by Eisai Co., Ltd. using SAS® for Windows (SAS Institute, 
Cary, NC, version 8.2 or later). 
The full analysis set population was used for all the analyses. Data were 
summarized descriptively according to treatment. For continuous variables, descriptive 
statistics are generally presented where applicable (including number of subjects [N], 
percentage of subjects [%], arithmetic mean [mean] and standard deviation [SD]). 
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Results 
 
Demographics and baseline characteristics 
In Study 001, 36 healthy male subjects were randomized: 28 to active treatment 
and 8 to vehicle. Thirty-three of these completed the study and three did not (two 
because of adverse events and one because of subject choice) (Figure 2-1). 
Demographics and baseline characteristics were generally similar among all the 
treatment groups (Table 2-2). 
 
Skin irritation and photosensitivity 
In the skin irritation test in Study 001, four subjects had a positive reaction 
30 min after removal of the Finn Chamber® (Table 2-3). One subject, who experienced 
application site edema without erythema at the site of the ‘‘no application’’ chamber as 
a treatment-emergent adverse event, improved without treatment and the reaction was 
considered not related to the study drug. Three subjects experienced faint application 
site erythema, one at the site of no treatment, one at the white petrolatum site and one at 
the 0.2% E6005 site. These were not classified as adverse events, because assessment 
investigators considered the erythema in these cases to be related to physical contact 
with the chamber. Photosensitivity testing was negative in all the participants. 
 
Safety and tolerability 
In Study 001, 4 of 28 subjects (14.3%) in the E6005 ointment treatment group 
and 1 of 8 (12.5%) in the vehicle treatment group had at least one treatment-emergent 
adverse event (Table 2-4). One subject, who experienced application site edema in the 
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patch test/ photopatch test, is described earlier. Two subjects in the 0.1% E6005 
ointment group experienced increased alanine aminotransferase. One discontinued the 
study on day 13 because of subject choice and improved without treatment. This 
elevation was considered to be possibly related to the study drug. The second 
participant continued the study, improved without treatment and the elevation was 
considered not related to the study drug. One subject in the 0.2% E6005 ointment 
treatment group and one in the vehicle treatment group in Cohort 3 experienced 
erythema, which occurred in the application area and in a non-application area. Both 
participants discontinued the study on Day 16, improved without treatment and the 
reactions were considered not related to the study drug. Deaths and other serious or 
severe adverse events (Grade 3 or higher) were not observed. Laboratory parameters, 
vital signs, electrocardiogram parameters and ophthalmological examination findings 
did not change clinically. 
 
Pharmacokinetic profile 
Plasma concentrations of E6005 and the metabolite M11 were below the lower 
limit of quantification (1 ng/ml) at all the sampling points in all the subjects, so it was 
not possible to obtain any meaningful pharmacokinetic data (Table 2-5). 
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Discussion 
Neither skin irritation nor photosensitization was observed in subjects treated 
with E6005 ointment or vehicle ointment, according to Japanese and International 
Contact Dermatitis Research Group criteria. In addition, there was no specific adverse 
reaction reported at any E6005 concentration up to 0.2% in this study. These results, 
including the assessments according to Japanese criteria (33), indicate no safety 
concerns for skin application of E6005 ointment or vehicle, including skin irritation, 
phototoxicity or light urticaria. 
Burning sensation and pruritus at the site of application, which are the 
commonly reported adverse reactions associated with tacrolimus ointment (36), were 
not observed in the present study. Nausea, vomiting, headache and weight loss, which 
are the commonly reported adverse reactions associated with other PDE4 inhibitors (20, 
21), were not observed in the present study. 
In all the healthy volunteers, plasma concentrations of E6005 and its metabolite 
M11 were below the limit of quantification at all the sampling points during the 5-day 
repeated application of E6005 ointment. The present findings are consistent with the 
results obtained when testing healthy skin in rats (22). 
In conclusion, the present data indicate that E6005 ointment is safe and well 
tolerated in healthy volunteers, although the results should be interpreted with caution 
because of the small number of healthy subjects included. Further studies in patients 
with atopic dermatitis are necessary to evaluate the safety of E6005 ointment applied to 
larger areas throughout the body for longer periods. 
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Table 2-1 Schedule of Each Step in E6005-J081-001 
Within-Period 
Day 
Total Day  
Outpatient Inpatient Discharge (Outpatient) 
Screening Period I Period II  (Follow-up) (Follow-up) 
-28 to -1 0 1 to 3 4, 6 8 1, 3, 5 7 to 11 12   
-28 to -1 0 1 to 3 4, 6 8 9, 11, 13 15 to 19 20 22  
Matters to be 
performed 
Screening 
examinations 
Admission in 
the study 
institution and 
prior 
examinations 
Patch 
test/photopatch 
test 
Assessment 
Assessment 
and prior 
examinations 
for Period II 
Drug 
application 
(once 
daily) 
Drug 
application 
(twice daily) 
Assessment Follow-up examinations 
(Follow-up 
examinations) 
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Table 2-2. Subject demographics and baseline characteristics 
 Vehicle E6005 ointment All subjects Parameter 0.01% 0.03% 0.1% 0.2% Total 
 (n=8) (n=7) (n=7) (n=7) (n=7) (n=28) (n=36) 
Age (years) 25.8±4.5 25.4±2.4 24.7±3.7 27.1±3.7 28.7±5.6 26.5±4.1 26.3±4.2 22, 36 22, 29 21, 30 23, 33 22, 36 21, 36 21, 36 
Height (cm) 175.34±4.26 172.93±4.42 174.59±2.90 177.36±5.98 173.13±4.11 174.50±4.60 174.69±4.48 169.5, 181.1 168.5, 182.1 168.9, 177.2 170.4, 186.7 168.9, 180.9 168.5, 186.7 168.5, 186.7 
Body weight (kg) 68.83±6.16 63.99±3.13 65.63±4.61 70.50±6.13 64.06±2.47 66.04±4.89 66.66±5.24 62.8, 80.2 60.4, 70.1 60.6, 72.8 61.0, 78.2 60.7, 67.6 60.4, 78.2 60.4, 80.2 
BMI (kg/m2) 22.38±1.57 21.40±0.70 21.53±1.26 22.41±1.82 21.40±0.65 21.69±1.22 21.84±1.31 21.0, 24.8 20.8, 22.4 20.3, 23.6 20.5, 24.8 20.4, 22.2 20.3, 24.8 20.3, 24.8 
TEWLa (g/m2h) 
12.23±5.43 8.89±1.56 10.31±1.91 13.16±9.70 9.56±1.70 10.48±5.07 10.87±5.12 
7.3, 24.3 5.6, 10.1 8.1, 13.5 6.6, 34.6 6.0, 11.1 5.6, 34.6 5.6, 34.6 
BMI: body mass index, SD: standard deviation, TEWL: transepidermal water loss. 
Upper row: Mean±standard deviation, lower row: minimum, maximum 
a: Calculated from the average of measured values on the left upper back and the right upper back 
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Table 2-3. Skin irritation test results (International Contact Dermatitis Research 
Group criteria) 
 No 
treatment 
White 
petrolatu
m 
Vehicle 
E6005 
 0.01% 0.03% 0.1% 0.2% 
Interpretation (n=36) (n=36) (n=36) (n=36) (n=36) (n=36) (n=36) 
Skin irritation test (patch test)        
No reaction 34  (94.4%) 
35 
 (97.2%) 
36 
 (100%) 
36 
 (100%) 
36 
 (100%) 
36 
 (100%) 
35 
 (97.2%) 
Doubtful reaction (faint erythema only) 1  (2.8%) 
1 
 (2.8%) 0 0 0 0 
1 
 (2.8%) 
Weak positive reaction (erythema, 
infiltration, possibly papules) 0 0 0 0 0 0 0 
Strong positive reaction (erythema, 
infiltration, papules, vesicles) 0 0 0 0 0 0 0 
Extreme positive reaction (intense 
erythema, infiltration, coalescing vesicles) 0 0 0 0 0 0 0 
Irritant reaction of a different type 1  (2.8%) 0 0 0 0 0 0 
Photosensitivity test (photopatch test)        
Negative reaction 36  (100%) 
36 
 (100%) 
36 
 (100%) 
36 
 (100%) 
36 
 (100%) 
36 
 (100%) 
36 
 (100%) 
Doubtful reaction; faint erythema only 0 0 0 0 0 0 0 
Weak positive reaction; erythema, 
infiltration, passively papules 0 0 0 0 0 0 0 
Strong positive reaction; erythema, 
infiltration, papules, vesicles 0 0 0 0 0 0 0 
Extreme positive reaction; intense 
erythema and infiltration and coalescing 
vesicles 
0 0 0 0 0 0 0 
Irritant reaction of different type 0 0 0 0 0 0 0 
Light urticaria 1  (2.8%) 0 
1 
 (2.8%) 0 0 0 0 
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Table 2-4. Treatment-emergent adverse events 
MedDRA System organ class and preferred term a 
Vehicle 
E6005 
0.01% 0.03% 0.1% 0.2% 
(n=8) (n=7) (n=7) (n=7) (n=7) 
Any adverse event 1 (12.5%) 
1 
(14.3%) 0 
2 
(28.6%) 
1 
(14.3%) 
General disorders and administration site conditions      
Application site edema 0 1 (14.3%) 0 0 0 
Investigations      
Alanine aminotransferase increased 0 0 0 2 (28.6%) 0 
Skin and subcutaneous tissue disorders      
Erythema 1 (12.5%) 0 0 0 
1 
(14.3%) 
a: Medical Dictionary for Regulatory Activities, version 17.1 
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Table 2-5. Number of subjects with plasma concentrations of E6005 or M11 above 
the lower limit of quantification 
 
Vehicle 
E6005 
0.01% 0.03% 0.1% 0.2% 
(n=8) (n=7) (n=7) (n=7) (n=7) 
E6005 0 0 0 0 0 
M11 0 0 0 0 0 
The lower limit of quantification was 1.00 ng/mL. 
29 
 
   Period I  First half of Period II  
Second half 
of Period II   
   Days 1–8  Days 9–14  Days 15–22   
   
Patch test and 
Photopatch 
test 
 
1 g on day 9, 
2 g on day 11, 
5 g on day 13 
 
5 g twice 
daily on days 
15–19 
  
          
  
 
Cohort 1 
(9 subjects) 
 0.01% E6005 
(7 active, 
 2 vehicle) 
 0.01% E6005 
(7 active, 
 2 vehicle) 
 
 
    
          
          
 
 
 
Cohort 2 
(9 subjects) 
 0.03% E6005 
(7 active, 
 2 vehicle) 
 0.03% E6005 
(7 active, 
 2 vehicle) 
 
 
36 subjects 
randomized 
    
         
         
 
 
Cohort 3 
(9 subjects) 
 
0.1% E6005 
(7 active, 
 2 vehicle) 
 
0.1% E6005 
(7 active, 
 2 vehicle) 
 
1 patient in the active group was 
withdrawn on day 13 because of 
subject choice. 
1 patient in the vehicle group was 
withdrawn on day 16 because of an 
adverse event. 
     
          
          
  
 
Cohort 4 
(9 subjects) 
 0.2% E6005 
(7 active, 
 2 vehicle) 
 0.2% E6005 
(7 active, 
 2 vehicle) 
 1 patient in the active group was 
withdrawn on day 16 because of an 
adverse event.     
Figure 2-1. Design and subject allocation schema for Study 001. 
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Chapter 3. 
 
A Phase I/II Study of E6005 in Japanese Patients with Atopic 
Dermatitis 
 
Summary 
 
Introduction: Phosphodiesterase type 4 (PDE4) inhibition is a well-known 
anti-inflammatory mechanism. However, the clinical use of PDE4 inhibitors has been 
compromised by the occurrence of mechanism-associated adverse reactions, which 
often limit the maximum tolerated dose. To minimize systemic exposure, a topically 
active PDE4 inhibitor with low transdermal bioavailability could be clinically useful. 
The purpose of this study was to evaluate the safety, tolerability and pharmacokinetics 
of topical application of a novel topical PDE4 inhibitor, E6005, and to assess the 
efficacy of E6005 in patients with atopic dermatitis. 
Methods: This randomized, investigator-blinded, vehicle-controlled, multiple ascending 
dose study included 40 adult male patients with atopic dermatitis, who were randomly 
assigned to 10 days of treatment with either E6005 ointment (0.01, 0.03, 0.1 or 0.2%) or 
vehicle ointment. 
Results: Of 81 patients screened, 40 who had typical lesions on their posterior trunk 
were randomized into the study. One patient receiving 0.03% E6005 treatment 
discontinued because of acute gout and one receiving vehicle treatment discontinued 
because of progression of atopic dermatitis. Plasma concentrations of E6005 were 
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below the limit of quantification (1 ng/ml). The targeted lesion severity scores 
decreased in a concentration-dependent manner in patients treated with E6005. This 
drop was significant in the 0.2% E6005 ointment treatment group (mean percent 
change: -54.30%, p=0.007).  
Conclusion: E6005 ointment exhibited acceptable safety and tolerability. Topical 
application of E6005 ointment resulted in very low systemic exposure to E6005 in 
patients with atopic dermatitis. E6005 ointment showed anti-inflammatory efficacy in 
adult patients with atopic dermatitis. 
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Introduction 
 
Atopic dermatitis is the most common skin disease, affecting a large number of 
children, adults, and their families (1). Although a high percentage of atopic dermatitis 
cases arise and go into remission during childhood, atopic dermatitis may also develop 
in adolescents and adults (9). Worldwide prevalence of atopic dermatitis ranges from 
0.2 to 25%, and the prevalence in developing countries has markedly increased in recent 
decades. In developed countries with the highest prevalence, the disease has reached a 
steady level (2, 3). Most patients with atopic dermatitis can control their skin disease 
with topical therapy and skin care. However, eczematous skin lesions in some patients 
do not respond to treatment with moisturizers, topical corticosteroids or topical 
calcineurin inhibitors, while some patients experience immediate flare-ups after tapering 
topical anti-inflammatory therapy (1, 10). There is an unmet need for new medical 
treatment options for these patients. 
E6005 (molecular weight: 472.49) was developed as a novel PDE4 inhibitor 
for topical use (22). PDE4 is expressed in several types of inflammatory cells (37). 
PDE4 activity is elevated in the leukocytes of patients with atopic dermatitis (17), and it 
reduces cyclic adenosine monophosphate (cAMP) responses to stimulation (14), leading 
to leukocyte hyperactivity and inflammation (18, 19). E6005 shows potent and selective 
inhibition of PDE4, and suppresses cytokine production by lymphocytes and monocytes. 
In mouse models, the topical application of E6005 produces anti-inflammatory effects, 
with reduced expression of cytokines and adhesion molecules (22). Topical E6005 
treatment also showed acute antipruritic activity in a mouse model of chronic dermatitis 
(25), with inhibition of itch-associated protease-activated receptor 2 (26), and decreased 
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excitation of itch-relevant dorsal root ganglion neurons (24). 
Although several PDE4 inhibitors have been developed, their use has thus far 
been compromised by the occurrence of mechanism-associated adverse reactions, 
including nausea, vomiting, headache and weight loss, which often limit the maximum 
tolerated dose (20, 21). To minimize systemic exposure, a topically active PDE4 
inhibitor with low transdermal bioavailability could be clinically useful. It previously 
reported that the topical application of E6005 ointment was safe and well tolerated in 
healthy volunteers (27). The objective of the present study was to evaluate the safety, 
tolerability and pharmacokinetics, and to assess the efficacy of topical E6005 ointment 
in male Japanese patients with atopic dermatitis. The outcome assessments in this trial 
were the severity scores of targeted lesions on the back, the Severity Scoring of Atopic 
Dermatitis (SCORAD) indexes (38), the Eczema Area and Severity Index (EASI) 
scores (39) and laboratory parameters.
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Materials and Methods 
 
This randomized, investigator-blinded, vehicle-controlled study to assess the 
safety and efficacy of E6005 ointment was undertaken at the Kyushu Clinical 
Pharmacology Research Clinic in Japan. The study was performed in full compliance 
with the International Conference on Harmonization, all applicable Good Clinical 
Practice guidelines, and local regulations in Japan. The study was approved by the 
institutional investigational review board and registered at www.ClinicalTrials.gov 
(NCT01179880). All patients provided written informed consent. 
 
Study population 
Patients eligible for the present study were Japanese men aged 20 to 65 years 
with mild-to-severe atopic dermatitis, diagnosed according to the ‘‘Guidelines for 
Management of Atopic Dermatitis’’ of the Japanese Dermatological Association (40). 
To be included, patients needed to have evaluable typically eczematous skin lesions on 
their posterior trunk (targeted lesion) to explore the efficacy of topical E6005 ointment 
application. Patients were excluded if they had additional skin diseases that would 
interfere with the study results. Patients were required to stop all topical atopic 
dermatitis therapy except for white petrolatum (such as topical corticosteroids and 
calcineurin inhibitors) at least 1 week before baseline evaluation, and to discontinue any 
systemic therapy (antihistamines, systemic corticosteroids, cyclosporine, tacrolimus), 
phototherapy and photochemotherapy at least 2 weeks before baseline evaluation.  
Inclusion Criteria: 
 Japanese adult male patients with a confirmed diagnosis of atopic dermatitis 
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according to “Guidelines for Management of Atopic Dermatitis” by the Japanese 
Dermatological Association 
 Patients with evaluable typical eczema on the back (posterior trunk) 
 Male subjects aged 20 years and over and under 65 years at the time of providing 
written informed consent 
 Virile men who and whose partner agreed to take adequate contraceptive measures 
during the study 
 Provided written informed consent of their free will 
 Were willing and able to comply with all the requirements of the protocol 
Exclusion Criteria: 
 Patients complicated with eye symptoms (e.g., cataract, retinal detachment), Kaposi 
varicelliform eruption, molluscum contagiosum or impetigo contagiosa 
 Patients who had an existing condition or a history of a severe allergy such as 
anaphylactic shock, anaphylactic reaction and anaphylactoid reaction or drug 
allergy/hypersensitivity to E6005 or any of the excipients 
 Patients who received any concomitant ethical drugs or any phototherapies within 
14 days before Baseline. Subjects were allowed to use external steroids and 
tacrolimus ointment up to 8 days before Baseline and white petrolatum throughout 
the study period 
 Patients with any infection that required hospitalization or intravenous/oral 
treatment with antibiotic/antiviral/antifungal drug(s) within 28 days before Baseline 
 Patients who had an existing condition or a history of any malignant tumor, 
lymphoma, leukemia, or lymphoproliferative disorders, which does not include 
non-melanoma skin cancers (e.g., squamous cell carcinoma and basal cell 
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carcinoma) that were completely removed and have not metastasized for 5 years 
 Patients who could not discontinue prohibited concomitant medication or therapy 
 From Baseline to the end of follow-up period or early discontinuation 
 Topical agents (e.g., cosmetics, pharmaceutical cosmetics). However, 
white petrolatum was permitted throughout the study. 
 Caffeinated food or beverage (e.g., coffee, tea, chocolate, and coke). For 
laboratory tests at Baseline, any caffeinated food or beverage (e.g., coffee, 
tea, chocolate, and coke) except for tea (e.g., black tea and green tea) was 
prohibited from 10 hours before Baseline. 
 From 72 hours before Baseline to the end of follow-up period or early 
discontinuation 
 Alcohol 
 From 7 days before Baseline to the end of follow-up period or early 
discontinuation 
 Topical steroids 
 Tacrolimus ointment 
 Food or beverage containing grapefruit 
 From 14 days before Baseline to the end of follow-up period or early 
discontinuation 
 Ethical drugs, except for topical steroids, and tacrolimus ointment 
 Phototherapies 
 Over-the-counter medications, nutritional supplements, vitamins, and 
herbal preparations (including Chinese medicines) 
 Blood component collection 
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 From 28 days before Baseline to the end of follow-up period or early 
discontinuation 
 Smoking or consumption of nicotine products (e.g., nicotine gum and 
nicotine patch) 
 Herbal preparations containing St. John’s Wort known to induce 
cytochrome P450 
 Whole blood collection (≥200 mL, <400 mL) 
 From 84 days before Baseline to the end of follow-up period or early 
discontinuation 
 Blood transfusion 
 Whole blood collection (≥400 mL) 
 From 112 days before Baseline to the end of follow-up period or early 
discontinuation 
 Participation in another clinical trial of an investigational drug or device 
 Patients with active syphilis, human immunodeficiency virus (HIV), or viral 
hepatitis (B or C) as demonstrated by positive on laboratory examination 
 Patients who had an existing condition or a history of unstable ischemic heart 
disease, cardiac failure congestive (New York Heart Association class III or IV), 
cerebral infarction, or cerebral hemorrhage 
 Prolongation of QTc interval (> 450 msec) demonstrated on repeated 
electrocardiograms (ECGs), using Bazett’s or Friedericia’s correction 
 Suffering from psychotic disorder(s) and/or unstable recurrent affective disorder(s) 
evident by use of antipsychotics or had had a suicide attempt(s) within 2 years 
before Baseline 
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 History of drug or alcohol dependency or abuse within 2 years before Baseline, or 
current user of psychotropic drugs for recreation other than therapeutic purpose 
 Presence of a progressive central nervous system (CNS) disease, including 
degenerative CNS diseases and progressive tumors 
 Scheduled for surgery during the projected course of the study 
 Evidence of any disease listed below that could affect the subject’s safety or study 
conduct or any disease (e.g., cardiac, respiratory, gastrointestinal, renal disease) 
judged by the investigator(s) to be clinically significant 
 Uncontrolled diabetes mellitus (e.g., requiring insulin) 
 Active inflammatory bowel disease, or peptic ulcer 
 Autoimmune diseases (e.g., collagen disorder) 
 Inborn error of metabolism 
 Indicating at least one of the following abnormal findings at the screening period:  
 Systolic blood pressure ≥140 mmHg, or diastolic blood pressure ≥90 mmHg 
 Heart rate <40/min, or ≥100/min 
 Body mass index (BMI) <18.0 kg/m2, or ≥30.0 kg/m2 
BMI (kg/m2) = weight (kg) / [height (m) × height (m)] 
 Hemoglobin <10.0 g/dL 
 White blood cells (WBC) <3,000/μL 
 Platelet <75,000/μL 
 Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3×
upper limit of normal (ULN) 
 Total bilirubin >1.5×ULN 
 Serum creatinine >1.5×ULN 
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 Patients who had any condition that would make him/her, in the opinion of the 
investigator, unsuitable for the study 
 
Investigational drugs 
E6005 (Methyl 4-[({3-[6,7-dimethoxy-2-(methyl amino)quinazolin-4-yl] 
phenyl}amino)carbonyl]benzoate, molecular weight: 472.49) ointment and vehicle 
(ointment base that did not include E6005) were manufactured by Eisai Co, Ltd and 
were used in present study. 
 
Study design 
Patients were randomized into four cohorts of 10 each, according to E6005 
ointment concentration (0.01, 0.03, 0.1 and 0.2%). Ointment was applied once on day 1, 
twice daily on days 2 through 9, and once on day 10. Eight patients in each cohort were 
treated with 5 g of E6005 ointment and two patients were treated with 5 g of vehicle 
ointment, as randomly determined using the SAS RANUNI procedure (Figure 3-1). The 
ointment was applied first to the targeted lesion on the back, then to other regions of the 
trunk, and finally to the lower limbs if sufficient ointment remained, avoiding the head, 
neck and upper limbs. Assessment investigators and patients were blinded to the study 
drug applied. When no safety concerns arose within one cohort, the next cohort began 
treatment at a higher drug concentration. 
 
Assessments 
The safety profile was assessed with treatment-emergent adverse event 
reporting, based on the Common Terminology Criteria for Adverse Events (National 
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Cancer Institute, Bethesda, MD, version 4.02), clinical laboratory testing, 
electrocardiogram recording, vital signs and ophthalmological findings. 
The severity score (range: 0–15) of the targeted lesion on the back was used as 
an efficacy variable. The severity score was determined as the sum of intensity scores 
(0: none, 1: mild, 2: moderate and 3: severe) for each of five symptoms (erythema, 
edema and/or papulation, oozing and/or crust, excoriation, lichenification), according to 
the SCORAD index assessment procedure (38). Other efficacy variables included the 
EASI score (range: 0–72) (Figure 3-2) (39), the SCORAD index (range: 0–103) (Figure 
3-3), Pruritus score (Pruritus state during the day and Pruritus state during the night, 
range: 0–4) (Table 3-1) (41, 42), transepidermal water loss of the targeted lesion 
measured with a VapoMeter (Delfin Technologies Ltd., Kuopio, Finland), total 
immunoglobulin E, CCL17 (thymus and activation-regulated chemokine [TARC]), 
eosinophil counts and lactate dehydrogenase. 
 
Measurement of plasma concentrations of E6005 and its metabolite 
In Study 101, blood samples were collected pre-dose on days 1, 2, 5, 10, 11, 12 
and 13, and 1-, 2-, 4- and 8-h post-dose on days 1, 5 and 10. Plasma concentrations of 
E6005 and its major metabolite (the methyl ester hydrolysis product) were quantified 
with a validated liquid chromatography-tandem mass spectrometry method with a lower 
limit of quantification of <1 ng/ml (35). 
 
Statistical analysis 
The full analysis set population was used for all analyses. All the analyses were 
performed by Eisai Co., Ltd. using SAS® for Windows (SAS Institute, Cary, NC, 
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version 8.2 or later). Data were summarized descriptively according to treatment. For 
continuous variables, descriptive statistics are generally presented where applicable 
(including number of subjects [N], percentage of subjects [%], arithmetic mean [mean] 
and standard deviation [SD]). 
Descriptive summary statistics of target lesion severity score, EASI score, 
SCORAD index, and laboratory test results at each assessment and changes from 
baseline were evaluated according to treatment group. p values were also determined 
using a paired t-test for exploratory purposes. Differences in the severity scores of the 
targeted lesion (last observation carried forward: LOCF) were evaluated with an 
analysis of covariance (ANCOVA), with treatment as a factor and baseline score as a 
covariate. Differences in EASI score and SCORAD index (observed case) were 
analyzed using a linear mixed-effect model, with treatment and time as factors, baseline 
scores as covariates, subjects as random effects, and changes or percent changes from 
baseline on days 5 and 11 as repeated measurements (p<0.05 was considered 
significant). 
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Results 
 
Demographics and baseline characteristics 
Of the 81 patients screened, 40 who had typical lesions on their posterior trunk 
were randomized into the study. Of the 40 patients, one patient receiving the 0.03% 
E6005 ointment treatment discontinued because of acute gout and one other receiving 
the vehicle treatment in Cohort 2 discontinued because of progression of atopic 
dermatitis and Kaposi’s varicelliform eruption (Figure 3-4). Demographics and baseline 
characteristics were similar among all treatment groups (Table 3-2, 3). 
 
Safety and tolerability 
Two of 32 patients (6.3%) in the E6005 ointment treatment group and 1 of 8 
(12.5%) in the vehicle treatment group had at least one treatment-emergent adverse 
event (Table 3-4). One patient in the 0.03% E6005 ointment treatment group had gout, 
which occurred in a non-drug application area and improved even after application of 
the drug. A patient in the 0.2% E6005 ointment treatment group had enterocolitis, 
which improved despite continuation of the study drug; this patient also had a history of 
lower abdominal pain during constipation. Another patient in the vehicle treatment 
group in Cohort 2 experienced aggravated atopic dermatitis and Kaposi’s varicelliform 
eruption. None of these adverse events was considered to be related to the study drug. 
Deaths and other serious or severe adverse events (Grade 3 or higher) were not observed. 
Laboratory parameters, vital signs, electrocardiogram parameters and ophthalmological 
examinations did not change clinically. 
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Pharmacokinetic profile 
Plasma concentrations of E6005 were below the lower limit of quantification 
(1 ng/ml) at all the sampling points in all the subjects, so it was not possible to obtain 
any meaningful pharmacokinetic data (Table 3-5). The metabolite M11 was detected in 
the plasma at levels just above the lower limit of quantification (1 ng/ml) and <3 ng/ml 
in 3 of 36 patients (8.3%; in two receiving 0.1% E6005 ointment treatment and in one 
receiving 0.2% E6005 ointment treatment). 
 
Efficacy 
The severity scores of the targeted lesions 
Figure 3-5 shows representative photographs of improvement in the targeted 
lesion of a 20-year-old man, who received 0.2% E6005 ointment application. Results of 
outcome assessments are summarized in Table 3-6. The mean severity scores of the 
targeted lesions (LOCF) fell from 6.3/15 to 3.9/15 in the 0.03% E6005 treatment group 
(p<0.001, paired t-test), and from 7.0/15 to 3.3/15 in the 0.2% E6005 treatment group 
(p<0.001, paired t-test). The mean changes from baseline were 2.4 in the 0.03% E6005 
group (p=0.046, ANCOVA) and 3.8 in the 0.2% E6005 group (p=0.001, ANCOVA), 
compared with 0.6 in the vehicle treatment group (Figure 3-6). The mean percent 
change from baseline decreased in an E6005-concentration-dependent manner. The 
decrease was significant in the 0.2% E6005 group at 54.30%, compared with 11.39% in 
the vehicle treatment group (p=0.007; ANCOVA). 
 
EASI score 
The study drug was applied to all lesions on the patient’s trunk in the present 
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study. The mean trunk portion of the EASI score fell from 6.08/21.6 to 2.48/21.6 in the 
0.1% E6005 treatment group (p=0.008, paired t-test), and from 5.66/21.6 to 3.30/21.6 in 
the 0.2% E6005 treatment group (p=0.002, paired t-test). Although the study drug was 
not applied to the head, neck or upper limbs, the mean change in EASI score total from 
baseline was 7.14/72 in the 0.1% E6005 group (p=0.004, analysis of linear mixed-effect 
model), and 6.13/72 in the 0.2% E6005 group (p=0.035, analysis of linear mixed-effect 
model), compared with 2.31/72 in the vehicle treatment group (Figure 3-7). 
 
SCORAD index 
Objective SCORAD is calculated based on SCORAD-A (extent of eczema) and 
SCORAD-B (intensity of eczema), and then SCORAD index total is calculated based 
on Objective SCORAD and SCORAD-C (subjective symptoms), using the following 
formulae (38). 
Objective SCORAD=SCORAD-A / 5 + SCORAD-B × 7 / 2 
SCORAD=Objective SCORAD + SCORAD-C 
The mean change in the Objective SCORAD from baseline on Day 11 was 
8.99/83 in the 0.1% E6005 group (p=0.016, analysis of a linear mixed-effect model), 
compared with 2.57/83 in the vehicle treatment group (Table 3-6). On the other hand, 
the SCORAD-C from baseline on Day 11 significantly reduced in the 0.03% E6005 
group (p=0.038, paired t-test) and 0.1% E6005 group (p=0.003, paired t-test), but there 
was no statistically significant reduction compared with the vehicle group (Table 3-6). 
Consequently, the mean change in the SCORAD index total from baseline was 
11.40/103 in the 0.1% E6005 group (p=0.015, analysis of a linear mixed-effect model), 
compared with 4.20/103 in the vehicle treatment group (Figure 3-8). 
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Pruritus score 
Pruritus score is summarized in Table 3-6. Pruritus day scores were 
significantly reduced from baseline in the 0.01% E6005 group and 0.03% E6005 group 
(p=0.049 in each treatment group, paired t-test) at the end of study. For pruritus night 
score, there was no statistically significant reduction from baseline at the end of study in 
any treatment group at the end of study. 
 
Laboratory tests 
Although there were statistically significant reductions from baseline for 
transepidermal water loss, eosinophil counts, and lactate dehydrogenase in the E6005 
treatment group at the end of the study, there was no significant reduction in total 
immunoglobulin E or CCL17 (Table 3-6). 
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Discussion 
 
This study is to evaluate the safety, tolerability and pharmacokinetics of topical 
application of E6005 ointment, and the first study to assess the therapeutic effect of 
E6005 ointment compared with a vehicle in Japanese male patients with atopic 
dermatitis. Most participants had mild or moderate atopic dermatitis. E6005 ointment 
(0.01%, 0.03%, 0.1%, and 0.2%) was safe and well-tolerated when applied repeatedly 
for 10 days to patients with atopic dermatitis. 
Tacrolimus ointment is widely used in treating atopic dermatitis. The most 
common adverse effects of tacrolimus ointment are a burning sensation and pruritus at 
the site of application, occurring during the first few days of treatment (36). In previous 
study of patients with atopic dermatitis, no application site reaction, including burning 
sensation and pruritus, occurred with use of E6005 ointment. Although the present 
studies did not compare topical E6005 with tacrolimus, the present results indicate that 
E6005 ointment may have a safer profile. 
In all healthy volunteers, plasma concentrations of E6005 and its metabolite 
M11 were below the limit of quantification at all sampling points during the 5-day 
repeated application of E6005 ointment (27). The present findings are consistent with 
the results obtained when testing healthy skin in rats (22). Although E6005 was not 
detected in the plasma of any patient with atopic dermatitis in the present study, the 
metabolite M11 was detected in the plasma of three. These results suggest that the 
stratum corneum is a major barrier to E6005 absorption through the skin in humans (as 
in rats) and that a small quantity of E6005 is absorbed through eczematous lesions in 
humans. Furthermore, an in vitro metabolism study using liver microsomes from 
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humans and other animals showed rapid metabolism of E6005 to M11. Together these 
results suggest low absorption and rapid elimination of E6005 from the systemic 
circulation in humans. 
Nausea, vomiting, headache, and weight loss, which are the commonly 
reported adverse reactions associated with other PDE4 inhibitors (20, 21), were not 
observed in the present studies. PDE4 inhibitors are thought to produce a 
pharmacological response analogous to that of presynaptic α2-adrenoceptor inhibitors 
by elevating intracellular levels of cAMP in noradrenergic neurons (43). One way to 
evaluate the emetic potential of this class of drugs is to assess the anesthesia-reversing 
effect of PDE4 inhibitors in rats, which do not have a vomiting reflex (44). In a study 
using this model of emesis, the reversal of anesthesia with systemic E6005 
administration was less potent than that with cilomilast administration (22). 
Additionally, as discussed above, absorption of E6005 is restricted by the stratum 
corneum, and absorbed E6005 is rapidly metabolized to M11. Furthermore, the 
metabolite M11 is 100 times weaker than E6005 in suppressing cytokine production by 
human monocytes, possibly because of its lower cell membrane permeability (22). Thus, 
the adverse reactions commonly reported with the use of other PDE4 inhibitors are 
expected to be less common with topical E6005 use. 
Application of E6005 ointment reduced the intensity of atopic dermatitis 
symptoms. The severity score of the targeted lesion was reduced in an 
E6005-concentration-dependent manner, with a significant reduction in the 0.2% E6005 
treatment group (Figure 3-6). Patients receiving the 0.1% or 0.2% E6005 treatment had 
significantly greater improvement in most efficacy parameters than patients receiving 
the vehicle treatment. The reported minimal clinically important difference is 8.7/103 
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for the SCORAD index, 8.2/83 for the objective SCORAD index, and 6.6/72 for the 
EASI score (45). Therefore, the improvements seen in the 0.1% and 0.2% E6005 
treatment groups were clinically important, and without safety concerns. 0.2% was 
considered as the clinically recommended dose for E6005. 
The edema/papulation (swelling) and oozing/crust severity score of the target 
lesion showed an approximate 70-80% reduction in the 0.2% E6005 treatment groups, 
and the erythema (redness), excoriation (scratching), and lichenification scores showed 
a 30-50% reduction (Figure 3-6). The erythema (redness) and induration/papulation/ 
edema (thickness) EASI score showed a 50% reduction in the 0.2% E6005 treatment 
groups, and excoriation (scratching) and lichenification score showed a 20-40% 
reduction (Figure 3-7). These results suggest that 10-day application to a part of the 
body is not sufficient to evaluate the efficacy of E6005 ointment, and longer-term 
assessments with application to the entire body are required. 
In mouse models, E6005 application has an immediate anti-pruritic effect via a 
cAMP-protein kinase A-dependent pathway (22, 24–26). Histamine binding to the H1 
receptor does not affect the cAMP-protein kinase A-dependent pathway, but it does 
affect phospholipase C-dependent pathways, which results in allergic reaction 
hypersensitivity responses, including redness, itching, and swelling (46). PDE4 
inhibitors do not affect histamine-induced itch, but may alter itching caused by other 
mechanisms such as serine proteases and proteinase-activated receptor 2 (26). In the 
present study, the subjective symptom score (pruritus and sleep loss) in the SCORAD 
index decreased (approximately 40% reduction), but did not disappear (Table 3-6, 
Figure 3-8). Concomitant use of histamine H1 receptor antagonists may be important to 
maximize the antipruritic effect of PDE4 inhibitors. 
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In summary, the present data indicate that E6005 ointment is safe and well 
tolerated and that it improves inflammation in patients with atopic dermatitis. However, 
the present results should be interpreted with caution because of the small study 
population, and also because only adult male patients were assessed during 
hospitalization, the drug was not applied to the entire body, and the treatment was short 
term. Longer-term efficacy studies with application of E6005 ointment to areas 
throughout the body are required. 
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Table 3-1. Pruritus Score 
Item Description 
Day 
4. Very severe, interfering with daily activities 
3. Severe, very annoying, substantially interfering with daily activities 
2. Moderate, annoying and troublesome, may interfere with daily activities 
1. Mild, not annoying or troublesome 
0. None 
Night 
4. Very severe, interfering with sleep 
3. Severe, very annoying, substantially interfering with sleep 
2. Moderate, annoying and troublesome, may interfere with sleep 
1. Mild, not annoying or interfering with sleep 
0. None 
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Table 3-2. Demographics 
  E6005 Combined 
 Vehicle 0.01% 0.03% 0.1% 0.2% Total Total 
Category (N=8) (N=8) (N=8) (N=8) (N=8) (N=32) (N=40) 
Age (year)a 
Mean (SD) 27.3 (8.6) 25.5 (6.8) 24.5 (3.8) 29.3 (7.5) 29.4 (9.2) 27.2 (7.1) 27.2 (7.3) 
Median 25.0 22.0 23.5 28.5 26.5 24.0 24.0 
Min, Max 20, 45 20, 40 20, 33 23, 46 20, 42 20, 46 20, 46 
Height (cm) 
Mean (SD) 170.58 (8.04) 170.84 (4.85) 173.10 (5.77) 175.05 (4.85) 171.43 (5.20) 172.60 (5.20) 172.20 (5.81) 
Median 169.90 171.35 173.70 175.05 171.15 172.45 171.40 
Min, Max 161.7, 188.3 160.5, 177.1 163.3, 181.3 169.9, 184.2 162.1, 180.4 160.5, 184.2 160.5, 188.3 
Weight (kg) 
Mean (SD) 66.53 (8.97) 68.08 (7.47) 62.95 (12.19) 67.28 (7.44) 65.74 (9.42) 66.01 (9.09) 66.11 (8.96) 
Median 65.20 67.05 58.00 66.80 66.10 65.85 65.85 
Min, Max 55.2, 76.9 54.7, 79.6 51.3, 85.3 55.2, 81.6 54.1, 78.7 51.3, 85.3 51.3, 85.3 
BMI (kg/m2) 
Mean (SD) 22.90 (3.11) 23.39 (2.85) 20.93 (3.39) 21.95 (2.37) 22.35 (2.89) 22.15 (2.90) 22.30 (2.91) 
Median 22.05 22.55 19.75 21.55 22.35 22.10 22.10 
Min, Max 20.1, 29.0 18.8, 27.8 18.3, 28.0 19.0, 26.6 18.6, 25.9 18.3, 28.0 18.3, 29.0 
Percentages are based on the total number of subjects in relevant treatment group. 
BMI: body mass index 
a: Age is calculated at date of informed consent. 
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Table 3-3. Baseline characteristics 
  E6005 Combined 
 Vehicle 0.01% 0.03% 0.1% 0.2% Total Total 
Category (N=8) (N=8) (N=8) (N=8) (N=8) (N=32) (N=40) 
Severity of atopic dermatitis, n (%) 
Mild 1 (12.5) 2 (25.0) 3 (37.5) 2 (25.0) 2 (25.0) 9 (28.1) 10 (25.0) 
Moderate 5 (62.5) 3 (37.5) 5 (62.5) 4 (50.0) 5 (62.5) 17 (53.1) 22 (55.0) 
Severe 1 (12.5) 2 (25.0) 0 (0.0) 2 (25.0) 1 (12.5) 5 (15.6) 6 (15.0) 
Very Severe 1 (12.5) 1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.1) 2 (5.0) 
Atopic dermatitis duration (years) 
Mean (SD) 11.30 (8.61) 17.71 (9.69) 22.73 (6.02) 16.55 (7.34) 21.01 (8.66) 19.50 (8.05) 17.86 (8.71) 
Median 11.80 17.20 20.80 14.90 19.3 19.35 18.70 
Min, Max 0.8, 24.8 5.8, 36.7 14.8, 34.8 8.9, 28.9 11.9, 35.9 5.8, 36.7 0.8, 36.7 
Seasonal allergy, n (%) 
Absent 
Present 
8 (100.0) 8 (100.0) 7 (87.5) 8 (100.0) 8 (100.0) 31 (96.9) 39 (97.5) 
0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0) 0 (0.0) 1 (3.1) 1 (2.5) 
Allergic rhinitis, n (%) 
Absent 7 (87.5) 6 (75.0) 7 (87.5) 7 (87.5) 7 (87.5) 27 (84.4) 34 (85.0) 
Present 1 (12.5) 2 (25.0) 1 (12.5) 1 (12.5) 1 (12.5) 5 (15.6) 6 (15.0) 
Allergic conjunctivitis, n (%) 
Absent 8 (100.0) 7 (87.5) 8 (100.0) 8 (100.0) 8 (100.0) 31 (96.9) 39 (97.5) 
Present 0 (0.0) 1 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.1) 1 (2.5) 
Severity score of targeted eczema  
Mean (SD) 6.6 (1.3) 9.1 (3.1) 6.3 (1.8) 5.8 (2.0) 7.0 (2.0) 7.0 (2.5) 7.0 (2.3) 
Min, Max 5, 8 6, 15 4, 9 3, 8 5, 10 3, 15 3, 15 
EASI score 
Mean (SD) 15.98 (8.56) 28.74 (17.19) 12.96 (6.25) 13.74 (9.70) 16.05 (7.03) 17.87 (12.24) 17.49 (11.53) 
Min, Max 7.0, 32.0 8.2, 61.2 6.0, 25.0 1.4, 34.0 7.2, 28.0 1.4, 61.2 1.4, 61.2 
SCORAD Total 
Mean (SD) 43.04 (6.00) 52.55 (20.61) 40.89 (11.49) 38.14 (11.79) 41.48 (13.04) 43.26 (15.06) 43.22 (13.67) 
Min, Max 31.2, 52.5 24.0, 88.5 24.6, 56.2 23.1, 61.4 23.5, 56.8 23.1, 88.5 23.1, 88.5 
SCORAD-A 
Mean (SD) 54.4 (26.2) 66.0 (31.8) 44.1 (30.9) 42.1 (28.1) 36.3 (16.6) 47.1 (28.6) 48.6 (28.0) 
Min, Max 25, 90 15, 95 10, 95 10, 92 15, 70 10, 95 10, 95 
SCORAD-B 
Mean (SD) 7.0 (1.4) 9.0 (4.2) 6.9 (2.0) 6.8 (1.8) 8.1 (2.2) 7.7 (2.8) 7.6 (2.6) 
Min, Max 5, 9 4, 17 4, 10 5, 10 5, 11 4, 17 4, 17 
Objective SCORAD 
Mean (SD) 35.38 (7.75) 44.70 (18.83) 32.89 (8.81) 32.05 (10.69) 35.69 (10.14) 36.33 (13.14) 36.14 (12.17) 
Min, Max 23.5, 48.5 20.0, 78.5 20.0, 42.1 19.5, 53.4 20.5, 46.5 19.5, 78.5 19.5, 78.5 
SCORAD-C 
Mean (SD) 7.66 (3.41) 7.85 (3.01) 8.00 (4.42) 6.09 (1.96) 5.79 (3.94) 6.93 (3.44) 7.08 (3.41) 
Min, Max 2.4, 12.9 3.7, 12.6 3.0, 14.1 3.6, 8.9 2.4, 13.8 2.4, 14.1 2.4, 14.1 
Pruritus Score (day) 
Mean (SD) 2.0 (0.0) 2.5 (0.5) 2.3 (0.7) 2.0 (0.0) 2.4 (0.5) 2.3 (0.5) 2.2 (0.5) 
Min, Max 2, 2 2, 3 1, 3 2, 2 2, 3 1, 3 1, 3 
Pruritus Score (night) 
Mean (SD) 1.9 (0.4) 1.8 (0.5) 2.0 (0.8) 1.9 (0.6) 1.9 (0.6) 1.9 (0.6) 1.9 (0.6) 
Min, Max 1, 2 1, 2 1, 3 1, 3 1, 3 1, 3 1, 3 
Percentages are based on the total number of subjects in relevant treatment group. 
EASI: Eczema Area and Severity Index, EQ-5D: the EuroQol Group 5-Dimension Self-Report Questionnaire score, IgE: 
immunoglobulin E, LDH: lactic dehydrogenase, SCORAD: SCORing Atopic Dermatitis, CCL17: thymus and activation-regulated 
chemokine (TARC), TEWL: transepidermal water loss.  
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Table 3-3. Baseline characteristics (continued) 
  E6005 Combined 
 Vehicle 0.01% 0.03% 0.1% 0.2% Total Total 
Category (N=8) (N=8) (N=8) (N=8) (N=8) (N=32) (N=40) 
Targeted eczema area TEWL (g/m2h)  
Mean (SD) 30.15 (12.66) 23.19 (5.01) 40.64 (17.16) 28.81 (12.14) 24.18 (4.83) 29.20 (12.66) 29.39 (12.50) 
Min, Max 12.6, 56.2 13.2, 28.2 22.3, 68.1 14.8, 47.0 18.0, 32.7 13.2, 68.1 12.6, 68.1 
Non-eczema area TEWL (g/m2h) 
Mean (SD) 16.11 (5.92) 16.38 (6.06) 24.23 (7.56) 12.51 (3.79) 15.59 (3.26) 17.18 (6.79) 16.96 (6.57) 
Min, Max 10.1, 26.6 9.6, 25.7 13.9, 37.2 8.5, 20.8 11.5, 22.2 8.5, 37.2 8.5, 37.2 
Eosinophil counts (/μL) 
Mean (SD) 351.5 (214.6) 1065.0 (1075.3) 485.8 (328.2) 539.8 (324.7) 379.0 (181.1) 617.4 (623.7) 564.2 (573.7) 
Median 309.0 632.0 504.5 450.0 323.5 454.5 439.5 
Min, Max 89, 704 404, 3578 99, 1006 188, 1024 240, 794 99, 3578 89, 3578 
LDH (IU/L) 
Mean (SD) 174.9 (30.2) 270.1 (146.1) 227.1 (95.1) 195.6 (48.9) 196.5 (29.1) 222.3 (92.4) 212.9 (85.6) 
Median 182.5 236.0 191.0 185.0 186.5 194.0 187.5 
Min, Max 113, 205 153, 602 152, 446 132, 270 171, 257 132, 602 113, 602 
IgE (IU/mL) 
Median 290.0 1950.0 395.0 735.0 2350.0 980.0 735.0 
Min, Max 39, 23000 30, 25000 9, 5400 170, 4200 23, 7700 9, 25000 9, 25000 
CCL17 (pg/mL) 
Median 374.5 812.0 629.5 489.0 372.5 543.0 507.0 
Min, Max 302, 4010 507, 48000 206, 3040 146, 948 172, 1460 146, 48000 146, 48000 
EQ-5D 
Mean (SD) 0.9341 (0.1231) 
0.9420 
(0.1074) 
0.9710 
(0.0820) 
1.0000 
(0.0000) 
0.9341 
(0.1231) 
0.9618 
(0.0908) 
0.9563 
(0.0970) 
Median 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 
Min, Max 0.705, 1.000 0.768, 1.000 0.768, 1.000 1.000, 1.000 0.705, 1.000 0.705, 1.000 0.705, 1.000 
Skindex-16 Total Score 
Mean (SD) 36.3 (19.2) 45.1 (13.8) 42.5 (22.7) 29.1 (11.6) 33.8 (24.6) 37.6 (19.2) 37.4 (19.0) 
Median 36.5 49.0 38.5 26.0 27.5 31.5 34.0 
Min, Max 7, 70 19, 58 12, 72 18, 54 4, 84 4, 84 4, 84 
Percentages are based on the total number of subjects in relevant treatment group. 
EASI: Eczema Area and Severity Index, EQ-5D: the EuroQol Group 5-Dimension Self-Report Questionnaire score, IgE: 
immunoglobulin E, LDH: lactic dehydrogenase, SCORAD: SCORing Atopic Dermatitis, CCL17: thymus and activation-regulated 
chemokine (TARC), TEWL: transepidermal water loss.  
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Table 3-4. Treatment-emergent adverse events 
MedDRA System organ class and preferred term a 
Vehicle 
E6005 
0.01% 0.03% 0.1% 0.2% 
(n=8) (n=8) (n=8) (n=8) (n=8) 
Any adverse event 1 (12.5%) 0 
1 
(12.5%) 0 
1 
(12.5%) 
Gastrointestinal disorders      
Enterocolitis 0 0 0 0 1 (12.5%) 
Infections and infestations      
Kaposi's varicelliform eruption 1 (12.5%) 0 0 0 0 
Metabolism and nutrition disorders      
Gout 0 0 1 (12.5%) 0 0 
Skin and subcutaneous tissue disorders      
Dermatitis, atopic 1 (12.5%) 0 0 0 0 
a: Medical Dictionary for Regulatory Activities, version 17.1 
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Table 3-5. Number of subjects with plasma concentrations of E6005 or M11 above 
the lower limit of quantification 
 
Vehicle 
E6005 
0.01% 0.03% 0.1% 0.2% 
(n=8) (n=8) (n=8) (n=8) (n=8) 
E6005 0 0 0 0 0 
M11 0 0 0 2 (25.0%) 1 (12.5%) 
The lower limit of quantification was 1.00 ng/mL 
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Table 3-6. Mean changes in efficacy variables from baseline through Day 11 
 Vehicle E6005 
Variable  0.01% 0.03% 0.1% 0.2% 
 (n=8) (n=8) (n=8) (n=8) (n=8) 
Severity score, targeted lesion      
Day 1 (baseline), mean±SD 6.6±1.3 9.1±3.1 6.3±1.8 5.8±2.0 7.0±2.0 
Day 11(LOCF), mean±SD 6.0±2.5 7.8±3.2 3.9±1.8 3.9±2.5 3.3±1.7 
Mean change±SD -0.6±1.8 -1.4±2.3 -2.4±0.5 -1.9±2.4 -3.8±1.4 
95% CI of difference from vehicle a — -2.2, 1.7 -3.6, 0.0 -3.3, 0.4 -4.8, -1.2 
p-value a — 0.825 0.046 0.117 0.001 
Mean percent change±SD -11.39±33.03 -14.48±24.97 -41.06±16.50 -28.38±47.16 -54.30±17.44 
95% CI of difference from vehicle a — -37.41, 29.31 -60.56, 1.50 -47.92, 14.62 -74.08, -12.03 
p-value a — 0.806 0.061 0.286 0.007 
EASI score      
Day 1 (baseline), mean±SD      
Head and neck 0.90±0.77 2.23±2.33 0.53±0.68 1.49±0.89 1.84±0.77 
Trunk 6.83±3.07 10.24±6.12 5.59±2.33 6.08±3.66 5.70±2.21 
Upper limbs 2.90±1.44 5.18±3.45 2.05±1.62 2.58±2.42 3.35±2.08 
Lower limbs 5.35±3.92 11.10±6.36 4.80±2.47 3.60±3.78 5.20±4.82 
EASI score total 15.98±8.56 28.74±16.39 10.99±5.56 12.51±10.43 13.51±4.45 
Day 11, mean±SD      
Head and neck 0.80±0.66 2.01±1.78 0.41±0.50 0.98±0.46 1.05±0.50 
Trunk 5.96±3.46 9.49±5.48 4.07±1.95 2.48±1.57 3.30±1.50 
Upper limbs 2.66±1.81 4.65±2.62 1.89±1.21 0.95±0.82 2.08±1.57 
Lower limbs 4.86±3.98 9.55±4.49 3.60±2.08 2.20±3.06 3.50±2.94 
EASI score total 14.27±9.25 25.70±12.26 9.97±5.18 6.60±4.17 9.93±5.69 
EASI score total, mean change±SD -2.31±2.12 -3.04±7.54 -3.37±4.08 -7.14±6.15 -6.13±2.72 
95% CI of difference from vehicle b — -2.58, 5.71 -6.17, 2.03 -9.77, -1.82 -8.24, -0.31 
p-value b — 0.452 0.317 0.004 0.035 
SCORAD index      
Day 1 (baseline), mean±SD      
Objective SCORAD 35.38±7.75 44.70±18.83 32.89±8.81 32.05±10.69 35.69±10.14 
SCORAD-C 7.66±3.41 7.85±3.01 8.00±4.42 6.09±1.96 5.79±3.94 
SCORAD index total 43.04±6.00 52.55±20.61 40.89±11.49 38.14±11.79 41.48±13.04 
Day 11, mean±SD      
Objective SCORAD 33.07±11.16 43.56±14.98 27.01±9.11 23.06±6.11 28.69±10.66 
SCORAD-C 5.84±3.56 6.70±3.96 3.69±2.00 3.68±2.40 3.73±2.15 
SCORAD index total 38.91±11.00 50.26±17.31 30.70±9.24 26.74±7.09 32.41±11.52 
SCORAD total, mean change±SD -4.20±5.11 -2.29±9.25 -9.47±7.26 -11.40±10.91 -9.06±7.20 
95% CI of difference from vehicle b — -4.66, 10.50 -14.45, 0.90 -16.79, -1.82 -13.70, 1.21 
p-value b — 0.444 0.082 0.015 0.098 
Pruritus Score      
Day      
Day 1 (baseline), mean±SD 2.0±0.0 2.5±0.5 2.3±0.7 2.0±0.0 2.4±0.5 
Day 11 (LOCF), mean±SD 2.3±0.7 1.9±0.6 1.6±0.5 1.9±0.4 1.8±0.9 
Mean change from baseline±SD 0.3±0.7 -0.6±0.7 -0.6±0.7 -0.1±0.4 -0.6±1.1 
95% CI of difference from vehicle — -1.7, -0.1 -1.7, -0.1 -1.0, 0.2 -1.8, 0.1 
Night      
Day 1 (baseline), mean±SD 1.9±0.4 1.8±0.5 2.0±0.8 1.9±0.6 1.9±0.6 
Day 11 (LOCF), mean±SD 2.0±0.9 2.0±0.8 1.5±0.5 1.4±0.9 1.5±0.8 
Mean change from baseline±SD 0.1±0.8 0.3±0.7 -0.5±0.9 -0.5±0.8 -0.4±1.2 
95% CI of difference from vehicle — -0.7, 1.0 -1.6, 0.3 -1.5, 0.2 -1.6, 0.6 
CI: confidence interval, EASI: eczema area and severity index, LOCF: last observation carried forward, SCORAD:scoring atopic 
dermatitis, SD: standard deviation. 
a: p-values and 95% CIs were obtained from analysis of covariance with treatment as a factor and baseline scores as a covariate. 
b: p-values and 95% CIs were obtained from linear mixed-effect model with treatment and time as factors, baseline score as a 
covariate, subject as random effect, and changes or percent changes from baseline to days 5 and 11 as repeated measurements 
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Table 3-6. Mean changes in efficacy variables from baseline through Day 11 
(continued) 
 Vehicle E6005 
Variable  0.01% 0.03% 0.1% 0.2% 
 (n=8) (n=8) (n=8) (n=8) (n=8) 
TEWL (g/m2h), targeted eczema      
Day 1 (baseline), mean±SD 30.15±12.66 23.19±5.01 40.64±17.16 28.81±12.14 24.18±4.83 
Day 11 (LOCF), mean±SD 27.36±12.94 24.11±7.17 30.29±7.21 20.91±4.73 19.18±5.45 
Mean change from baseline±SD -2.79±12.45 0.93±3.39 -10.35±12.71 -7.90±10.71 -5.00±5.47 
95% CI of difference from vehicle — -6.07, 13.49 -21.05, 5.92 17.56, 7.34 -12.52, 8.10 
Eosinophile counts (/μL)      
Day 1 (baseline), mean±SD 351.5±214.6 1065.0±1075.3 485.8±328.2 539.8±324.7 379.0±181.1 
Day 11 (LOCF), mean±SD 312.6±234.5 745.0±731.2 301.0±228.1 441.6±312.3 275.3±134.5 
Mean change from baseline±SD 312.6±234.5 745.0±731.2 301.0±228.1 441.6±312.3 275.3±134.5 
95% CI of difference from vehicle — -585.1, 22.9 -376.9, 85.1 -188.2, 69.7 -184.0, 54.3 
LDH (IU/L)      
Day 1 (baseline), mean±SD 174.9±30.2 270.1±146.1 227.1±95.1 195.6±48.9 196.5±29.1 
Day 11 (LOCF), mean±SD 171.9±73.0 212.4±108.4 170.6±45.5 171.5±40.1 172.3±23.0 
Mean change from baseline±SD -3.0±59.8 -57.8±39.8 -56.5±65.3 -24.1±19.4 -24.3±16.2 
95% CI of difference from vehicle — -109.2, -0.3 -120.7, 13.7 -68.8, 26.5 -68.2, 25.7 
Total IgE (IU/mL)      
Day 1 (baseline), mean±SD 3441.5±7943.5 5835.0±8608.0 1154.1±1814.3 1335.0±1415.9 2491.0±(2575.6 
Day 11 (LOCF), mean±SD 3466.4±7939.8 5459.3±7433.3 1119.8±1623.7 1360.0±1476.8 2267.6±2316.0 
Mean change from baseline±SD 24.9±71.6 -375.8±1554.3 -34.4±239.5 25.0±112.4 -223.4±342.5 
95% CI of difference from vehicle — -1580.5, 779.3 -248.8, 130.3 -100.9, 101.2 -513.5, 17.0 
CCL17 (pg/mL)      
Day 1 (baseline), mean±SD 869.5±1277.5 6832.6±16644.9 918.9±963.6 478.6±252.3 627.0±505.4 
Day 11 (LOCF), mean±SD 1927.8±4313.8 3001.3±6014.5 842.5±1025.0 481.9±187.4 519.3±378.4 
Mean change from baseline±SD 1058.3±3043.8 -3831.4±10655.4 -76.4±310.2 3.3±177.6 -107.8±235.9 
95% CI of difference from vehicle — -13292.7, 3513.5 -3454.7, 1185.4 -3367.0, 1257.0 -3481.0, 1149.0 
CCL17: thymus and activation-regulated chemokine (TARC), CI: confidence interval, EASI: eczema area and severity index, 
LOCF: last observation carried forward, SCORAD: scoring atopic dermatitis, SD: standard deviation. 
a: p-values and 95% CIs were obtained from analysis of covariance with treatment as a factor and baseline scores as a covariate. 
b: p-values and 95% CIs were obtained from linear mixed-effect model with treatment and time as factors, baseline score as a 
covariate, subject as random effect, and changes or percent changes from baseline to days 5 and 11 as repeated measurements 
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 Prerandomization  Randomization  
 Screening Baseline Treatment Follow-up  
 ◄―――――――――――――► ◄――――► ◄―――――――――――――――► ◄――――――►  
    E6005   
   
R 
   
    (no treatment)  
    Vehicle   
      
 Day -28 Day -1 Day 0 Day 1 Day 1  Day 13  
R: Randomization 
Figure 3-1. Study design for E6005-J081-101 (shown as a cohort) 
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Row  
Head and 
Neck 
Upper 
Limbs Trunk 
Lower 
Limbs 
1 Erythema E E E E 
2 Induration/Papulation I I I I 
3 Excoriations Ex Ex Ex Ex 
4 Lichenification L L L L 
5 Total each Column E+I+Ex+L E+I+Ex+L E+I+Ex+L E+I+Ex+L 
6 Area Area Area Area Area 
7 Multiply Row 5 by Row 6 (E+I+Ex+L) x Area 
(E+I+Ex+L) 
x Area 
(E+I+Ex+L) 
x Area 
(E+I+Ex+L) 
x Area 
8  
(E+I+Ex+L) 
x Area  
x 0.10 
(E+I+Ex+L) 
x Area 
x 0.20 
(E+I+Ex+L) 
x Area 
x 0.30 
(E+I+Ex+L) 
x Area 
x 0.40 
9 Multiply row 7 by Row 8 H UL T LL 
10 
Total EASI  
(add together each column 
from Row 9) 
H+UL+T+LL 
 
Figure 3-2. EASI score 
The body was divided into four anatomic regions (head and neck, upper limbs, trunk, 
and lower limbs), and the items described below were assessed. It should be noted that 
the buttocks and feet were counted as part of the lower limbs, the internal axillae and 
groin were counted as part of the trunk, and the external axillae and hands were counted 
as part of the upper limbs. 
Area: The area within each body region with the key signs of inflammation was 
calculated as the percentage of the total area of the body region based on seven 
classifications (0: 0%, 1: 1 to 9%, 2: 10 to 29%, 3: 30 to 49%, 4: 50 to 69%, 5: 70 to 
89%, 6: 90 to 100%). Symptoms (e.g., pruritus), along with secondary signs (e.g., 
Rank severity of atopic lesions:  
0= none, 1= mild, 2=moderate, 3= severe  
Rank area of atopic involvement:  
0= none, 1= <10%, 2=10% to <30%, 
3= 30% to <50%, 4=50% to <70%,  
5= 70% to <90%, 6=90% to 100%  
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xerosis and scaling) was excluded from the area assessments. 
Symptoms: Each of the four body regions was assessed separately for the key signs of 
erythema (E), infiltration and/or papulation (I), excoriations (Ex), and lichenification 
(L). The average degree of severity of each sign in each of the four body regions was 
assessed based on the four classifications (0: none, 1: mild, 2: moderate, and 3: severe). 
The score was calculated for each region [(E+I+Ex+L) × Area], and then multiplied the 
head and neck score by 0.1, the upper limbs score by 0.2, the trunk score by 0.3, and the 
lower limbs score by 0.4. The Eczema Area and Severity Index (EASI) score (0 – 72) 
was obtained by summing the four scores calculated above.
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Figure 3-3. SCORAD index 
At each point of assessment, the percentage of eczema area to the entire body (area 
ratio, %) was calculated according to the area ratio in the assessment procedure of 
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SCORAD. This was reported as SCORAD-A (extent of eczema). 
At each point of assessment, the investigators divided the symptoms into five items 
(erythema, oedema/papulation, oozing/crust, excoriation, and lichenification) according 
to the assessment procedure of SCORAD, selected the average area for each item, 
assessed the severity based on four classifications (0: none, 1: mild, 2: moderate, and 3: 
severe). The dryness of the skin in non-eczema area was assessed based on four 
classifications (0: none, 1: mild, 2: moderate, and 3: severe). The sum of the six items 
was calculated to present SCORAD-B (intensity of eczema). 
Subjects evaluated the degree of “Pruritus” and “Sleep loss” associated with atopic 
dermatitis as an average over the 3 days before the assessments and filled in the 10 cm 
visual analogue scale in handwriting. Documentation of the results was included in the 
source documentation at the investigational site. This evaluation was conducted before 
all the examinations and assessments by the investigators, in order to avoid influences 
on the assessment of the subject. The investigators and clinical research coordinators 
checked the reported score to see if there were no inadequacy or inconsistency, 
measured the length from far left (cm) to the first decimal place. The sum of the two 
items was calculated the to produce SCORAD-C (subjective symptoms). 
The objective SCORAD score (0 – 83) and the SCORAD score (0 – 103) were 
calculated using the following formulae. 
Objective SCORAD = SCORAD-A / 5 + SCORAD-B × 7 / 2 
SCORAD = Objective SCORAD + SCORAD-C 
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 Cohort 1 
0.01% E6005 
(8 active, 
 2 vehicle) 
 
 
   
  
         
         
   
 
 
 Cohort 2 
0.03% E6005 
(8 active, 
 2 vehicle) 
 One patient in the active group was withdrawn on 
day 6 because of an adverse event. 
One patient in the vehicle group was withdrawn on 
day 6 because of progression of atopic dermatitis. 
81 patients 
assessed for 
eligibility 
  
40 patients 
randomized 
  
       
       
  
 
 Cohort 3 
0.1% E6005 
(8 active, 
 2 vehicle) 
 
 
   
   
         
         
   
41 patients 
excluded  
 Cohort 4 
0.2% E6005 
(8 active, 
 2 vehicle) 
 
 
   
  
Figure 3-4. Flow chart of patients included in E6005-J081-101 
Of the 81 patients screened, 40 who had typically eczematous skin lesions that were on 
their posterior trunk that could be evaluated were randomized into four groups of 10. 
Patients in each group were randomized (at a ratio of 4:1) to receive application of 
either 5 g of E6005 ointment or 5 g of vehicle ointment. Investigators and patients were 
blinded to application of the study drug. When no safety concerns arose within a cohort, 
the next cohort began treatment at a higher drug concentration. 
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A B 
 
Figure 3-5. Photographs of a targeted lesion in a 20-year-old participant treated with 
0.2% E6005 ointment. 
(A) Severity score at baseline was 9/15. Application of E6005 ointment reduced the 
intensity of edema/papulation, oozing/crust, excoriation, and lichenification, but not 
erythema.  
(B) Severity score on day 11 had fallen to 5/15. 
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Figure 3-6. Severity score of targeted lesions. 
The severity score (range: 0−15) of the targeted lesion was calculated as the sum of 
intensity scores (0: none, 1: mild, 2: moderate, and 3: severe) for each of five symptoms 
(erythema, edema and/or papulation, oozing and/or crust, excoriation, lichenification), 
according to the SCORAD index assessment procedure. Differences in the severity 
scores (last observation carried forward) were evaluated using ANCOVA, with 
treatment as a factor and baseline score as a covariate. Error bars show standard 
deviation. 
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Figure 3-7. EASI score. 
Differences in the EASI score (observed case) were analyzed using a linear 
mixed-effect model, with treatment and time as factors, baseline score as a covariate, 
subject as random effect, and changes from baseline as repeated measurements. 
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Figure 3-8. SCORAD index. 
Differences in the SCORAD index (observed case) were analyzed using a linear 
mixed-effect model, with treatment and time as factors, baseline score as a covariate, 
subject as random effect, and changes from baseline as repeated measurements. 
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Chapter 4. 
 
Concluding Remarks 
 
Atopic dermatitis is a common skin disorder (1). Individuals with atopic 
dermatitis have increased phosphodiesterase activity in their white blood cells, which 
leads to decreased cyclic AMP levels and loss of cAMP’s anti-inflammatory effects (14, 
17–19). For years, there has been interest in the use of phosphodiesterase inhibitors to 
treat chronic inflammatory diseases. However, the use of these drugs has been limited 
because of their systemic side effects (20, 21). E6005 is a novel phosphodiesterase 
inhibitor developed for topical use. Topical E6005 has shown anti-inflammatory and 
anti-pruritic effects in mouse models (22–26). 
I conduct two studies, one is to evaluate the safety and pharmacokinetics of 
E6005 ointment in healthy volunteers and another is to evaluate the safety, 
pharmacokinetics and efficacy of E6005 ointment in patients with atopic dermatitis (27, 
28). 
Thirty-eight healthy volunteers and 40 patients with atopic dermatitis 
participate in these randomized, investigator-blind, vehicle-controlled studies. The 38 
healthy volunteers undergo skin patch testing, photosensitivity testing, increasing dose 
testing, and repeated twice-daily dosing. The 40 patients with atopic dermatitis are 
divided into four cohorts, each of which underwent a 10-day course of topical treatment 
of lesions at a different drug concentration. The safety profile of E6005 is assessed with 
treatment-emergent adverse event reporting, clinical laboratory testing, 
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electrocardiogram recording, vital signs, and ophthalmological findings. E6005 is found 
to be as safe and well tolerated as petrolatum ointment, and plasma concentrations of 
the drug were below detectable levels in all participants. None of the participants 
experiences the most common side effects of systemic PDE4 inhibitor administration: 
nausea, vomiting, or headache. 
Additionally, I investigate the efficacy of a 10-day course of topical E6005 
ointment at four different concentrations, using vehicle ointment as a control. Efficacy 
is evaluated based on changes in the severity scores of targeted lesions, SORAD 
indexes, EASI scores, and laboratory parameters. Severity scores decreased in a 
concentration-dependent manner in the E6005 treatment groups, with a significant 
improvement in the 0.2% E6005 group compared with the vehicle group. 
Recently, Furue M, et al. have reported E6005 treatment is safe and effective in 
adults with atopic dermatitis (47) and Nemoto O, et al. have reported E6005 treatment 
is safe and effective in children with atopic dermatitis (48). These results suggest that 
E6005 ointment can provide a new treatment option for atopic dermatitis that avoids 
safety concerns associated with PDE4 inhibitors, while maintaining similar 
effectiveness. 
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